AC
GNMK

Armistice Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History

Armistice Capital’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-792,000
Closed -$11.2M – 133
2020
Q3 		$11.2M Buy
+792,000
New +$12.1M 0.41% 60

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Armistice Capital's GNMK Position: Q4 2020 in Review

Armistice Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 792,000 shares — an estimated $11.2M sold.

Armistice Capital first reported a position in GNMK in Q3 2020 and held it in 1 quarter. The position peaked at $11.2M in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Armistice Capital reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Armistice Capital sold 792,000 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $11.2M.
  • Armistice Capital first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 1 quarter.
  • Armistice Capital's GenMark Diagnostics, Inc position peaked at $11.2M in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Armistice Capital's 13F filing for Q4 2020, filed 16 Feb 2021.